HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

European OTC Results Round-Up: Recordati, Ipsen and Venture Life

You may also be interested in...



EMA Approves EU-Wide Rx-to-OTC Switch Of Fortacin

Premature ejaculation treatment Fortacin is set to become only the fifth drug to achieve an Rx-to-OTC switch through EMA's centralized procedure, expanding the burgeoning OTC men's sexual health category. 

RB Doubles R&D Spend In Search Of 'Game Changing’ OTC Innovation

With Reckitt's OTC sales falling 3% in 2020, the firm has committed to doubling its R&D spend in search of breakthrough product innovations.

RB Shows Scholl The Door, While Welcoming In Biofreeze

Reckitt is refocusing its consumer health portfolio by offloading the troubled Scholl brand and acquiring fast-growing US topical analgesic Biofreeze.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1135307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel